Abstracts Archive - Page 274 of 2425 - ACR Meeting Abstracts

Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Rebecca Haberman¹, Sydney Catron¹, Yu Veronica Sui¹, Sarah Moussavi¹, Soumya Reddy², Eileen Lydon³, Andrea Neimann¹, Alexis R Ogdie⁴, Mariana Lazar¹ and Jose Scher⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³New York University, New York, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…
Abstract Number: 1535 • ACR Convergence 2023
Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study
Ji In Jung¹, Jun Won Park², Song Jihun³, Seulggie Choi², Sun Jae Park³, Sang Min Park² and Eun Young Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University Graduate School, Seoul, South Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Previous studies on AAV have shown that the epidemiology and clinical features of GPA and MPA differ among countries. Considering their high mortality and…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
Abstract Number: 1521 • ACR Convergence 2023
Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis
Lisa Balistreri¹, Megan Sullivan¹, Florentina Berianu¹, Ernesto Ayala² and Andy Abril², ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: Autologous hematopoietic stem cell therapy (HSCT) is an effective therapy for patients with rapidly progressive systemic sclerosis (SSc) refractory to standard therapies. The disease…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 0959 • ACR Convergence 2023
Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis
Heetaek Yang¹, Rajan Bhandari¹, Saemi Han², Chanhyuk Park¹, Chen-Yu Wang², Emily Morris¹, Michael Whitfield¹ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease with multiple clinical and pathological manifestations including vascular involvement, immune activation, oxidative stress, and fibrosis. In…
Abstract Number: 0992 • ACR Convergence 2023
Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray
Sean Brown¹, John Hardin² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Enthesophytes consist of calcium deposition on tendons or ligaments that are proposed to form in response to localized inflammation of the enthesis, either idiopathic…
Abstract Number: 1153 • ACR Convergence 2023
Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches
Manush Sondhi¹, Warda Maqsood² and Sarwat Umer³, ¹Louisiana State University, Shreveport, LA, ²LSU Health Science Center, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA
Background/Purpose: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a relatively rare and often underdiagnosed inflammatory disorder. Its diagnosis can be challenging due to its…
Abstract Number: 1636 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
E. William St. Clair¹, Liangwei Wang², Ilias Alevizos², William A. Rees², Alan Baer³, Wan-Fai Ng⁴, Ghaith Noaiseh⁵ and Chiara Baldini⁶, ¹Duke University Medical Center, Durham, NC, ²Horizon Therapeutics, Rockville, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Pisa, Pisa, Italy
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 1532 • ACR Convergence 2023
Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis
Alberto Sulli¹, Rosanna Campitiello¹, Emanuele Gotelli¹, Andrea Cere¹, Elvis Hysa², Tamara Vojinovic², Carlotta Schenone¹, Carmen Pizzorni¹, Sabrina Paolino¹, Elisa Alessandri¹, Vanessa Smith³ and Maurizio Cutolo⁴, ¹Laboratory of Experimental Rheumatology and Academic Division of Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Ghent University Hospital, Gent, Belgium, ⁴Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: The progressive endothelial damage is one of the hallmarks of systemic sclerosis (SSc), an autoimmune connective tissue disease characterized by organ fibrotic involvement. Aminaphtone…
Abstract Number: 1638 • ACR Convergence 2023
CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
Tuyet-Hang Pham¹, Michael A. Smith¹, Nannette Mittereder¹, William A. Rees², Ilias Alevizos², E. William St. Clair³ and Claire Emson¹, ¹Horizon Therapeutics plc, Rockville, MD, ²Horizon Therapeutics, Rockville, MD, ³Duke University Medical Center, Durham, NC
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 1606 • ACR Convergence 2023
Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation
NaveenKumar K. Somanathapura, Claire Hoy, Srilakshmi Yalavarthi, Cyrus Sarosh, Bruna De Moraes Mazetto Fonseca, Caroline Ranger, Christine Rysenga, Ajay Tambralli, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: In first responding cells such as neutrophils and platelets, extracellular ATP released from activated or dying cells engages cell-surface receptors to launch proinflammatory and…
Abstract Number: 1541 • ACR Convergence 2023
Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA
Gatr-alnada Gheriani¹ and Petar Lenert², ¹University of Iowa Hospital and Clinics, Tiffin, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…
Abstract Number: 1414 • ACR Convergence 2023
Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
Philip J. Mease¹, Dafna Gladman², Iain McInnes³, Sue Cheng⁴, Stephen Colgan⁵, Yuri Klyachkin⁶, Lichen Teng⁷ and Nehal Mehta⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Amgen, Inc., Bradenton, FL, ⁵Amgen, Inc., Halton Hills, ON, Canada, ⁶Amgen, Inc., Lexington, KY, ⁷Amgen, Inc., Thousand Oaks, CA, ⁸George Washington University School of Medicine, Washington, DC
Background/Purpose: The prevalence of cardiometabolic diseases including obesity and diabetes is higher in patients with psoriatic arthritis (PsA) than those without PsA. Apremilast (APR) is…
Abstract Number: 1164 • ACR Convergence 2023
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Fabian Carranza Enriquez¹, Rosa-Elena Escobar-Cedillo², Saul Renan-Leon², Karina Arias Callejas³, Alejandra Enriquez-Luna², Graciliano Ramon-Diaz² and Carlos Pineda², ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ³Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico
Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].